The European Society of Urogenital Radiology is committed to improving knowledge and understanding about contrast media. There seemed to be little agreement about the best approach for the prevention of contrast mediuminduced nephrotoxicity or generalized adverse reactions and the use of intravascular contrast media in diabetic patients receiving metformin. There was also concern that there might be discrepancies between current practice and published recommendations on these subjects. The Contrast Media Safety Committee of the European Society of Urogenital Radiology has produced practical guidelines on these important topics based on wide consensus and extensive review of the literature. The details of the guidelines are presented in this review.
One of the aims of the European Society of Urogenital Radiology (ESUR) as stated in its by-laws is to promote research and improve knowledge about contrast media. In 1994 the Board of ESUR established a Contrast Media Safety Committee (CMSC) consisting of ESUR members with a major interest in contrast media research and representatives from companies that manufacture contrast agents. The CMSC focused its attention on the effects of contrast media on the kidney, prophylaxis against generalized reactions to contrast media, and the intravascular use of contrast agents in patients taking metformin. It was the definite impression of the CMSC that there is confusion and misunderstanding about these topics, with no consensus guidelines. The CMSC is also aware that there is confusion in other areas concerning contrast media, but the committee gave the previously mentioned subjects a high priority because they were considered to have an important impact on the daily work of most radiology departments.
Guidelines can be produced by opinion-based methods in which a group of experts simply reach consensus on a protocol or by evidence-based methods that rely on careful analysis of scientific evidence to determine which principles should be considered [1, 2] . Opinion-based methods are faster, require few resources, and have been used for many years by specialty societies and hospital committees [1] . The problem with this approach is that the recommendations may not be based on evidence and the process by which consensus was reached is often poorly documented. This makes it difficult for people outside the process to evaluate the rationale and invites speculation about conflict of interest and partiality [1] . Although evidence-based methods offer the best strategy to circumvent these problems, the lack of scientific evidence on some of the aspects of these topics and the time and resources required to produce evidence-based guidelines suggested the need for an interim process to produce temporary guidelines based on expert consensus with clear documentation of how that consensus was derived. The ESUR CMSC combined the Delphi process [1, 2] and expert consensus, which allowed a survey of the current practice and a review of the literature. The guidelines produced have the advantages of being easy to implement and are based on current practice that is supported by data published in scientific journals. In addition, they highlight the areas of uncertainty.
In this review the guidelines produced by the ESUR CMSC and areas of uncertainty are presented. The methods used to obtain these guidelines are described briefly.
Methods
A questionnaire compiled by the CMSC after surveying the current literature was circulated to members of the ESUR. In accordance with the Delphi process [1] [2] [3] [4] [5] , the participants were asked to grade each statement from 1 to 10 to indicate its importance. A score of 1 indicated that the statement was definitely not important, a score of 5 indicated that its importance was uncertain, and a score of 10 indicated that the statement was extremely important. The participants were asked not to use fractions in their ratings. Questionnaire statements also were provided and participants were asked to choose the most accurate state ment under the different headings. When appropriate, yes and no questions were used.
The answers were analyzed to establish the mean and standard deviation ratings for each statement. A mean score of 6 or more for any statement was considered positive for importance. For yes and no questions, a simple majority (Ͼ50%) was considered significant. The guidelines also were discussed at the ESUR scientific meetings (Sixth European Symposium on Uroradiology, Strasbourg, France, September 1998, for contrast medium nephrotoxicity [CMN] and Seventh European Symposium on Urogenital Radiology, London, UK, September 2000, for prevention of generalized reactions) and comments from more than 250 participants at each meeting were acquired [3, 5] . Based on a review of the literature, guidelines on avoiding metformin-induced lactic acidosis after intravascular use of contrast media were established [4] .
Guidelines on the prevention of CMN are presented in Table 1 and those for the prevention of generalized reactions are presented in Table 2 . Guidelines on avoiding metformin-induced lactic acidosis after intravascular use of contrast media are presented in Table 3 .
Wide variation in the received answers, incompatibility of some of the answers with the published literature, and the lack of clear information in the literature have brought to our attention several areas of uncertainty in the subjects of CMN (Table 4 ) and the prevention of generalized reactions to iodinated contrast media (Table 5 ).
Discussion
The survey on the topic of CMN showed general agreement that patients with diabetic nephropathy have the highest risk of this complication and confirmed the importance of hydration and the use of low osmolar media as prophylactic measures against contrast nephropathy [3] . However, CMN can develop despite implementing the previously mentioned prophylactic measures. A recent report has indicated that the prophylactic oral administration of the antioxidant acetylcystine (600 mg twice daily, on the day before and the day of administration of the contrast agent, for a total of 2 days) and hydration (0.45% saline intravenously, 1 mL/kg of body weight per hour for 12 h before and 12 h after contrast injection) prevented CMN in patients with chronic renal impairment [6] . However, in that study, a relatively small dose of contrast medium (75 mL of 300 mgI/mL) was used and the number of patients was small. It is feasible that acetylcystine does not offer protection against CMN when larger doses of contrast media are used, as during interventional vascular procedures. Further studies are required to confirm the effectiveness of this antioxidant and to elucidate the areas of uncertainty (Table 4) revealed by the survey [3] .
Guidelines based on the opinion of approximately 300 professionals on the prevention of generalized reactions were obtained (Table 2 ) [5] . Most responders used corti- 
Definition
Contrast medium nephrotoxicity is a condition in which an impairment in renal function (an increase in serum creatinine by Ͼ25%, or 44 mol/L) occurs within 3 days after the intravascular administration of a contrast medium without an alternative etiology Risk factors Raised S-creatinine levels, in particular those secondary to diabetic nephropathy Dehydration Congestive heart failure Age Ͼ70 years Concurrent administration of nephrotoxic drugs, e.g., nonsteroidal anti-inflammatory drugs In patients with risk factor(s)
Make sure the patient is well hydrated: give at least 100 mL orally, e.g. soft drinks, or intravenously, e.g., normal saline, depending on the clinical situation, per hour starting 4 h before to 24 h after contrast administration; in hot climates, increase fluid volume Use low molar or iso-osmolar contrast medium Stop administration of nephrotoxic drugs for at least 24 h Consider alternative imaging techniques that do not require the administration of iodinated contrast medium Do not give high osmolar contrast medium Do not administer large doses of contrast medium Do not administer mannitol and diuretics, in particular loop diuretics Do not perform multiple studies with contrast medium within a short period costeroid prophylaxis and non-ionic agents in patients considered at increased risk for contrast medium reaction (asthmatics and patients with a history of contrast media reaction or allergy) [5] . This is similar to Cohan et al.'s findings in their survey of the Society of Uroradiology (USA) [7] . However, the value of using corticosteroid prophylaxis remains contentious [8] , and the current opinion as to whether corticosteroid prophylaxis should be used with non-ionic agents is divided. This division was reflected in a survey from the United Kingdom showing that 55% of responders used corticosteroid prophylaxis and 45% did not [9] . Our survey, like that of Cohan et al. When absorption or leakage into the circulation is possible, take the same precautions as those for intravascular administration Table 3 . Guidelines for the administration of contrast medium to diabetics taking metformin [4] Serum creatinine levels should be measured before intravascular administration of contrast medium in every diabetic patient treated with biguanides; low osmolar contrast medium always should be used in these patients Elective studies
If the serum creatinine is normal, the radiologic examination should be performed and intake of metformin stopped from the time of the study; metformin should not be resumed for 48 h and should be restarted only if renal function/serum creatinine remains within the normal range If renal function is abnormal, the metformin should be stopped and the contrast study should be delayed for 48 h; metformin should be restarted 48 h later if renal function or serum creatinine is unchanged Emergency cases
If the serum creatinine is normal, the study may proceed as suggested for elective patients If the renal function is abnormal (or unknown), the physician should weigh the risks and benefits of contrast administration; alternative imaging techniques should be considered; if administration of contrast medium is deemed necessary, the following precautions should be implemented Metformin therapy should be stopped The patient should be hydrated (e.g., at least 100 mL/h of soft drinks or intravenous saline up to 24 h after contrast medium administration; in hot climates, more fluid should be given) Monitor renal function (serum creatinine), serum lactic acid, and blood pH Look for symptoms of lactic acidosis (vomiting, somnolence, nausea, epigastric pain, anorexia, hyperpnea, lethargy, diarrhea, thirst); blood test results indicative of lactic acidosis: pH Ͻ7.25 and lactic acid Ͼ5 mmol Table 4 . Areas of uncertainty regarding contrast medium nephrotoxicity [3] Importance of persistent nephrogram on CT after administration of contrast medium Relevance of a history of contrast medium-induced nephrotoxicity in a patient with normal S-creatinine levels at the time of the administration of contrast medium Long-term effects of contrast medium on renal function Threshold nephrotoxic dose of contrast medium at various levels of S-creatinine Importance of the various causes of renal impairment, except diabetic nephropathy, in the development of contrast medium-induced nephropathy Threshold rise in S-creatinine used to define contrast medium-induced nephropathy Extent of the contribution of tubular and hemodymic effects to the pathogenesis of contrast medium-induced nephropathy [7] , indicated that a wide variety of regimes with different doses, numbers of doses, and frequencies are used for giving corticosteroid prophylaxis. The minimum lead time for corticosteroids to be given before contrast medium administration is not known, but the lead time is unlikely to be less than 6 h. The mechanism by which corticosteroid prophylaxis works is not completely understood [10] . Several areas of uncertainty were identified (Table 5 ) and they require further research. The use of contrast media in patients receiving the oral hypoglycaemic drug metformin is controversial. Metformin is excreted from the body mainly via the kidneys; if renal excretion is reduced, metformin accumulates in the body and may cause the development of the serious complication of lactic acidosis because contrast media can induce acute reduction in renal function retention of metformin in the body and lactic acidosis may develop in diabetic patients taking this drug after the intravascular injection of contrast agents. However, most patients with metformin-induced lactic acidosis after the administration of iodinated contrast media either had renal dysfunction before the procedure or continued to use metformin despite the development of CMN [4] . The risk of developing lactic acidosis for patients with normal serum creatinine (serum creatinine Ͻ 130 mol/L) and who received metformin before the radiographic procedure is very limited [4, 11] . The ESUR CMSC reviewed the literature on this subject and produced guidelines for administration of contrast media to diabetics taking metformin (Table 3) .
The ESUR surveys documented a wide variety of practice for prophylaxis of renal and nonrenal contrast medium reactions. Significant areas of uncertainty remain, reflect the paucity of relevant information in the literature, and highlight the need for further research (Tables 4, 5 ). The guidelines (Tables 1-3 ) produced by the ESUR can be found on the Internet (www.esur.org). They are being adopted by many colleagues in Europe and have been endorsed by several European health authorities. Our experience suggests that guidelines based on consensus are useful and can have a great impact on the management of patients.
